GSK (LSE:GSK) shares rose 2.5% to 1,815 pence on Monday after the pharmaceutical company reported results from clinical trials of two lung cancer treatments.
The company said Jideytro met the primary endpoint in its trial, with 94% of patients recording complete or partial tumour shrinkage.
Ris-Rez Trial Shows Reduction in Risk of Death
GSK also reported positive late-stage trial results for Ris-Rez, a treatment licensed from Hansoh Pharmaceutical (HK:3692).
According to the company, Ris-Rez reduced the risk of death by 54% compared with standard chemotherapy in patients with relapsed small cell lung cancer.
Leave a Reply